Lilly CEO says 700,000 seniors started GLP-1 drugs after Medicare coverage
Eli Lilly CEO David Ricks said 700,000 seniors have started GLP-1 medicines since new Medicare coverage launched in July. Ricks also said 70% of those patients are taking Lilly drugs, according to the latest metrics cited on how the coverage is expanding access.
Eli Lilly CEO David Ricks said 700,000 seniors have started GLP-1 medicines since new Medicare coverage launched in July, according to CNBC.
Ricks said 70% of those patients are taking Lilly drugs. The figures were presented as the latest metrics on how the new coverage is expanding access to GLP-1 medicines.
THE QUESTIONS THIS EVENT LEAVES BEHIND
What eligibility conditions apply to the seniors included in this count?
How were the 700,000 patients identified and measured?
What factors contributed to Lilly drugs accounting for 70% of the reported starts?
How might expanded Medicare coverage affect future demand for GLP-1 medicines?
YOUR QUESTION
Does this story leave you with another question?
Send us the question the report did not answer. It may become the next question IAQ investigates.
GLOBAL CURIOSITY MAP · AUGUST 2026